Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC
Liquid biopsy tests have become an integral part of the molecular diagnosis of patients with non-small cell lung cancer (NSCLC). We describe a new test panel that uses very low input (20 ng) of cell-free nucleic acids extracted from human plasma, which is designed to yield results in less than 72 h....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/2/155 |
| _version_ | 1827598978105999360 |
|---|---|
| author | Hestia Mellert Jordan Reese Leisa Jackson Victoria Maxwell Chérie Tschida Gary A. Pestano |
| author_facet | Hestia Mellert Jordan Reese Leisa Jackson Victoria Maxwell Chérie Tschida Gary A. Pestano |
| author_sort | Hestia Mellert |
| collection | DOAJ |
| description | Liquid biopsy tests have become an integral part of the molecular diagnosis of patients with non-small cell lung cancer (NSCLC). We describe a new test panel that uses very low input (20 ng) of cell-free nucleic acids extracted from human plasma, which is designed to yield results in less than 72 h. In this study, we performed novel amplicon-based targeted next-generation sequencing with a semiconductor-based system, the Ion GeneStudio S5 Prime. The analytic performance of the assay was evaluated using contrived and retrospectively collected clinical specimens. The cumulative percent coefficient of variation for the new test process was very precise at 8.4% for inter-day, 4.0% for inter-operator and 3.4% for inter-instrument. We also observed significant agreement (95.7–100%) with an orthogonal, high-sensitivity droplet digital™ Polymerase Chain Reaction (ddPCR) test. This method offers a valuable supplement to assessing targeted mutations from blood while conserving specimens and maintaining sensitivity, with rapid turn-around times to actionable results. |
| first_indexed | 2024-03-09T04:03:42Z |
| format | Article |
| id | doaj.art-87c50d5d684247908d933632be9a9a19 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-09T04:03:42Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-87c50d5d684247908d933632be9a9a192023-12-03T14:10:17ZengMDPI AGDiagnostics2075-44182021-01-0111215510.3390/diagnostics11020155Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLCHestia Mellert0Jordan Reese1Leisa Jackson2Victoria Maxwell3Chérie Tschida4Gary A. Pestano5Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USABiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USABiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USABiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USABiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USABiodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, USALiquid biopsy tests have become an integral part of the molecular diagnosis of patients with non-small cell lung cancer (NSCLC). We describe a new test panel that uses very low input (20 ng) of cell-free nucleic acids extracted from human plasma, which is designed to yield results in less than 72 h. In this study, we performed novel amplicon-based targeted next-generation sequencing with a semiconductor-based system, the Ion GeneStudio S5 Prime. The analytic performance of the assay was evaluated using contrived and retrospectively collected clinical specimens. The cumulative percent coefficient of variation for the new test process was very precise at 8.4% for inter-day, 4.0% for inter-operator and 3.4% for inter-instrument. We also observed significant agreement (95.7–100%) with an orthogonal, high-sensitivity droplet digital™ Polymerase Chain Reaction (ddPCR) test. This method offers a valuable supplement to assessing targeted mutations from blood while conserving specimens and maintaining sensitivity, with rapid turn-around times to actionable results.https://www.mdpi.com/2075-4418/11/2/155diagnosticsnon-small cell lung cancer (NSCLC)liquid biopsynext generation sequencing (NGS) |
| spellingShingle | Hestia Mellert Jordan Reese Leisa Jackson Victoria Maxwell Chérie Tschida Gary A. Pestano Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC Diagnostics diagnostics non-small cell lung cancer (NSCLC) liquid biopsy next generation sequencing (NGS) |
| title | Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC |
| title_full | Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC |
| title_fullStr | Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC |
| title_full_unstemmed | Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC |
| title_short | Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC |
| title_sort | targeted next generation sequencing of liquid biopsy samples from patients with nsclc |
| topic | diagnostics non-small cell lung cancer (NSCLC) liquid biopsy next generation sequencing (NGS) |
| url | https://www.mdpi.com/2075-4418/11/2/155 |
| work_keys_str_mv | AT hestiamellert targetednextgenerationsequencingofliquidbiopsysamplesfrompatientswithnsclc AT jordanreese targetednextgenerationsequencingofliquidbiopsysamplesfrompatientswithnsclc AT leisajackson targetednextgenerationsequencingofliquidbiopsysamplesfrompatientswithnsclc AT victoriamaxwell targetednextgenerationsequencingofliquidbiopsysamplesfrompatientswithnsclc AT cherietschida targetednextgenerationsequencingofliquidbiopsysamplesfrompatientswithnsclc AT garyapestano targetednextgenerationsequencingofliquidbiopsysamplesfrompatientswithnsclc |